Allogeneic endometrial regenerative cells: An "Off the shelf solution" for critical limb ischemia?

Michael Murphy, Hao Wang, Amit N. Patel, Suman Kambhampati, Niren Angle, Kyle Chan, Annette M. Marleau, Andrew Pyszniak, Ewa Carrier, Neil H. Riordan, Thomas E. Ichim

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Critical limb ischemia (CLI) is an advanced form of peripheral artery disease which is responsible for approximately 100,000 amputations per year in the US. Trials to date have reported clinical improvement and reduced need for amputation in CLI patients receiving autologous bone marrow or mobilized peripheral blood stem cells for stimulation of angiogenesis. While such treatments are currently entering Phase III trials, practical and scientific pitfalls will limit widespread implementation if efficacy is proven. Hurdles to be overcome include: a) reduced angiogenic potential of autologous cells in aged patients with cardiovascular risk factors; b) invasiveness/adverse effects of bone marrow extraction and G-CSF mobilization, respectively; and c) need for on-site cellular manipulation. The Endometrial Regenerative Cell (ERC) is a mesenchymal-like stem cell derived from the menstrual blood that is believed to be associated with endometrial angiogenesis. We discuss the possibility of using allogeneic ERCs as an "off the shelf" treatment for CLI based on the following properties: a) High levels of growth factors and matrix metalloprotease production; b) Ability to inhibits inflammatory responses and lack of immunogenicity; and c) Expandability to great quantities without loss of differentiation ability or karyotypic abnormalities.

Original languageEnglish
Article number45
JournalJournal of Translational Medicine
Volume6
DOIs
StatePublished - 2008

Fingerprint

Stem cells
Bone
Blood
Ischemia
Extremities
Amputation
Metalloproteases
Granulocyte Colony-Stimulating Factor
Bone Marrow
Intercellular Signaling Peptides and Proteins
Peripheral Arterial Disease
Mesenchymal Stromal Cells
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Allogeneic endometrial regenerative cells : An "Off the shelf solution" for critical limb ischemia? / Murphy, Michael; Wang, Hao; Patel, Amit N.; Kambhampati, Suman; Angle, Niren; Chan, Kyle; Marleau, Annette M.; Pyszniak, Andrew; Carrier, Ewa; Riordan, Neil H.; Ichim, Thomas E.

In: Journal of Translational Medicine, Vol. 6, 45, 2008.

Research output: Contribution to journalArticle

Murphy, M, Wang, H, Patel, AN, Kambhampati, S, Angle, N, Chan, K, Marleau, AM, Pyszniak, A, Carrier, E, Riordan, NH & Ichim, TE 2008, 'Allogeneic endometrial regenerative cells: An "Off the shelf solution" for critical limb ischemia?', Journal of Translational Medicine, vol. 6, 45. https://doi.org/10.1186/1479-5876-6-45
Murphy, Michael ; Wang, Hao ; Patel, Amit N. ; Kambhampati, Suman ; Angle, Niren ; Chan, Kyle ; Marleau, Annette M. ; Pyszniak, Andrew ; Carrier, Ewa ; Riordan, Neil H. ; Ichim, Thomas E. / Allogeneic endometrial regenerative cells : An "Off the shelf solution" for critical limb ischemia?. In: Journal of Translational Medicine. 2008 ; Vol. 6.
@article{cee69870e8fd4c888e45d65eedca5542,
title = "Allogeneic endometrial regenerative cells: An {"}Off the shelf solution{"} for critical limb ischemia?",
abstract = "Critical limb ischemia (CLI) is an advanced form of peripheral artery disease which is responsible for approximately 100,000 amputations per year in the US. Trials to date have reported clinical improvement and reduced need for amputation in CLI patients receiving autologous bone marrow or mobilized peripheral blood stem cells for stimulation of angiogenesis. While such treatments are currently entering Phase III trials, practical and scientific pitfalls will limit widespread implementation if efficacy is proven. Hurdles to be overcome include: a) reduced angiogenic potential of autologous cells in aged patients with cardiovascular risk factors; b) invasiveness/adverse effects of bone marrow extraction and G-CSF mobilization, respectively; and c) need for on-site cellular manipulation. The Endometrial Regenerative Cell (ERC) is a mesenchymal-like stem cell derived from the menstrual blood that is believed to be associated with endometrial angiogenesis. We discuss the possibility of using allogeneic ERCs as an {"}off the shelf{"} treatment for CLI based on the following properties: a) High levels of growth factors and matrix metalloprotease production; b) Ability to inhibits inflammatory responses and lack of immunogenicity; and c) Expandability to great quantities without loss of differentiation ability or karyotypic abnormalities.",
author = "Michael Murphy and Hao Wang and Patel, {Amit N.} and Suman Kambhampati and Niren Angle and Kyle Chan and Marleau, {Annette M.} and Andrew Pyszniak and Ewa Carrier and Riordan, {Neil H.} and Ichim, {Thomas E.}",
year = "2008",
doi = "10.1186/1479-5876-6-45",
language = "English",
volume = "6",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Allogeneic endometrial regenerative cells

T2 - An "Off the shelf solution" for critical limb ischemia?

AU - Murphy, Michael

AU - Wang, Hao

AU - Patel, Amit N.

AU - Kambhampati, Suman

AU - Angle, Niren

AU - Chan, Kyle

AU - Marleau, Annette M.

AU - Pyszniak, Andrew

AU - Carrier, Ewa

AU - Riordan, Neil H.

AU - Ichim, Thomas E.

PY - 2008

Y1 - 2008

N2 - Critical limb ischemia (CLI) is an advanced form of peripheral artery disease which is responsible for approximately 100,000 amputations per year in the US. Trials to date have reported clinical improvement and reduced need for amputation in CLI patients receiving autologous bone marrow or mobilized peripheral blood stem cells for stimulation of angiogenesis. While such treatments are currently entering Phase III trials, practical and scientific pitfalls will limit widespread implementation if efficacy is proven. Hurdles to be overcome include: a) reduced angiogenic potential of autologous cells in aged patients with cardiovascular risk factors; b) invasiveness/adverse effects of bone marrow extraction and G-CSF mobilization, respectively; and c) need for on-site cellular manipulation. The Endometrial Regenerative Cell (ERC) is a mesenchymal-like stem cell derived from the menstrual blood that is believed to be associated with endometrial angiogenesis. We discuss the possibility of using allogeneic ERCs as an "off the shelf" treatment for CLI based on the following properties: a) High levels of growth factors and matrix metalloprotease production; b) Ability to inhibits inflammatory responses and lack of immunogenicity; and c) Expandability to great quantities without loss of differentiation ability or karyotypic abnormalities.

AB - Critical limb ischemia (CLI) is an advanced form of peripheral artery disease which is responsible for approximately 100,000 amputations per year in the US. Trials to date have reported clinical improvement and reduced need for amputation in CLI patients receiving autologous bone marrow or mobilized peripheral blood stem cells for stimulation of angiogenesis. While such treatments are currently entering Phase III trials, practical and scientific pitfalls will limit widespread implementation if efficacy is proven. Hurdles to be overcome include: a) reduced angiogenic potential of autologous cells in aged patients with cardiovascular risk factors; b) invasiveness/adverse effects of bone marrow extraction and G-CSF mobilization, respectively; and c) need for on-site cellular manipulation. The Endometrial Regenerative Cell (ERC) is a mesenchymal-like stem cell derived from the menstrual blood that is believed to be associated with endometrial angiogenesis. We discuss the possibility of using allogeneic ERCs as an "off the shelf" treatment for CLI based on the following properties: a) High levels of growth factors and matrix metalloprotease production; b) Ability to inhibits inflammatory responses and lack of immunogenicity; and c) Expandability to great quantities without loss of differentiation ability or karyotypic abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=51649102810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649102810&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-6-45

DO - 10.1186/1479-5876-6-45

M3 - Article

C2 - 18713449

AN - SCOPUS:51649102810

VL - 6

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 45

ER -